Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

COMMENTED

Macular DiseasesRetinal Diseases

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina.

Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ

doi: 10.1097/IAE.

Macular Diseases

Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

JAMA Ophthalmol.

Subhi Y, Krogh Nielsen M, Molbech CR, Krüger Falk M, Singh A, Hviid TVF, Nissen MH, Sørensen TL

doi: 10.1001/jamaophthalmol.

Macular DiseasesRetinal Diseases

Six-year outcomes in neovascular age-related macular degeneration with ranibizumab

Int J Ophthalmol.

Jacob J, Brié H, Leys A, Levecq L, Mergaerts F, Denhaerynck K, Vancayzeele S, Van Craeyveld E, Abraham I, MacDonald K

doi: 10.18240/ijo.2017.01.14.

Macular DiseasesRetinal Diseases

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Br J Ophthalmol.

Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group

doi: 10.1136/bjophthalmol-

Macular Diseases

Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry

Ophthalmology.

Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D

doi: 10.1016/j.ophtha.2019.10.006.

Macular Diseases

Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration

Ophthalmology.

Nguyen V, Daien V, Guymer R, Young S, Hunyor A, Fraser-Bell S, Hunt A, Gillies MC, Barthelmes D; Fight Retinal Blindness! Study Group

doi: 10.1016/j.ophtha.

Macular Diseases

Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab

JAMA Ophthalmol.

Parikh R, Avery RL, Saroj N, Thompson D, Freund KB

doi: 10.1001/jamaophthalmol.2019.1947.

COMMENTED

Macular Diseases

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

★ 3 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

JAMA Ophthalmol

Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, Vajas A, Papp A, Gabor V, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Bressler NM

doi: 10.1001/jamaophthalmol.2020.5053

Macular DiseasesRetinal Diseases

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles

Br J Ophthalmol

Vofo BN, Beykin G, Levy J, Chowers I

doi: 10.1136/bjophthalmol-2021-319054

Related content

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Six-year outcomes in neovascular age-related macular degeneration with ranibizumab

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry

Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration

Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles